BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Pelletier AL, Nicaise-Roland P. Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol 2016; 5(1): 44-50 [DOI: 10.5497/wjp.v5.i1.44]
URL: https://www.wjgnet.com/2220-3192/full/v5/i1/44.htm
Number Citing Articles
Cátia Rocha, Joana Afonso, Paula Lago, Bruno Arroja, Ana I. Vieira, Claudia C. Dias, Fernando Magro. Accuracy of the new rapid test for monitoring adalimumab levelsTherapeutic Advances in Gastroenterology 2019; 12: 175628481982823 doi: 10.1177/1756284819828238
Neeraj Narula, Brian Lauzon, John K. Marshall. Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology 2019; 54(6): 712 doi: 10.1080/00365521.2019.1621367